MedKoo Cat#: 522527 | Name: MF-63
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MF-63 is a novel and selective mPGES-1 inhibitor. MF63 potently inhibited the human mPGES-1 enzyme (IC(50) = 1.3 nM), with a high degree (>1000-fold) of selectivity over other prostanoid synthases. In rodent species, MF63 strongly inhibited guinea pig mPGES-1 (IC(50) = 0.9 nM) but not the mouse or rat enzyme. MF63 did not cause NSAID-like gastrointestinal toxic effects, such as mucosal erosions or leakage in the KI mice or nonhuman primates, although it markedly inhibited PGE(2) synthesis in the KI mouse stomach.

Chemical Structure

MF-63
MF-63
CAS#892549-43-8

Theoretical Analysis

MedKoo Cat#: 522527

Name: MF-63

CAS#: 892549-43-8

Chemical Formula: C23H11ClN4

Exact Mass: 378.0672

Molecular Weight: 378.82

Elemental Analysis: C, 72.92; H, 2.93; Cl, 9.36; N, 14.79

Price and Availability

Size Price Availability Quantity
5mg USD 300.00 2 weeks
10mg USD 550.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MF-63; MF63; MF 63
IUPAC/Chemical Name
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile
InChi Key
BVFLHOOKHPFDCT-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H11ClN4/c24-15-8-9-18-19(10-15)16-6-1-2-7-17(16)21-22(18)28-23(27-21)20-13(11-25)4-3-5-14(20)12-26/h1-10H,(H,27,28)
SMILES Code
N#CC1=CC=CC(C#N)=C1C2=NC3=C4C=CC(Cl)=CC4=C5C=CC=CC5=C3N2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Microsomal prostaglandin E synthase-1 (mPGES-1) is a terminal prostaglandin E(2) (PGE(2)) synthase in the cyclooxygenase pathway. Inhibitors of mPGES-1 may block PGE(2) production and relieve inflammatory symptoms.
Product Data
Biological target:
MF63 is a selective and orally active inhibitor of mPGES-1.
In vitro activity:
MF63 enhanced the expression of multiple metallothionein 1 (MT1) isoforms as well as endogenous antagonists of IL-1 and IL-36. The expression of IL-6, by contrast, was down-regulated. These genes were also essential in functional and interaction network analyses. The effects of MF63 were consistent in qRT-PCR analysis, whereas the effects of ibuprofen overlapped only partly with MF63. Reference: Br J Pharmacol. 2020 Sep;177(18):4134-4146. https://pubmed.ncbi.nlm.nih.gov/32449517/
In vivo activity:
In rodent species, MF63 strongly inhibited guinea pig mPGES-1 (IC(50) = 0.9 nM) but not the mouse or rat enzyme. When tested in the guinea pig and a knock-in (KI) mouse expressing human mPGES-1, the compound selectively suppressed the synthesis of PGE(2), but not other prostaglandins inhibitable by nonsteroidal anti-inflammatory drugs (NSAIDs), yet retained NSAID-like efficacy at inhibiting lipopolysaccharide-induced pyresis, hyperalgesia, and iodoacetate-induced osteoarthritic pain. Reference: J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. https://pubmed.ncbi.nlm.nih.gov/18524979/
Solvent mg/mL mM comments
Solubility
DMSO 36.5 96.35
DMSO:PBS (pH 7.2) (1:2) 0.3 0.79
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 378.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tuure L, Pemmari A, Hämäläinen M, Moilanen T, Moilanen E. Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. Br J Pharmacol. 2020 Sep;177(18):4134-4146. doi: 10.1111/bph.15142. Epub 2020 Aug 10. PMID: 32449517; PMCID: PMC7443472. 2. Hétu PO, Ouellet M, Falgueyret JP, Ramachandran C, Robichaud J, Zamboni R, Riendeau D. Photo-crosslinking of proteins in intact cells reveals a dimeric structure of cyclooxygenase-2 and an inhibitor-sensitive oligomeric structure of microsomal prostaglandin E2 synthase-1. Arch Biochem Biophys. 2008 Sep 1;477(1):155-62. doi: 10.1016/j.abb.2008.04.038. Epub 2008 May 6. PMID: 18498757. 3. Finetti F, Terzuoli E, Giachetti A, Santi R, Villari D, Hanaka H, Radmark O, Ziche M, Donnini S. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity. Endocr Relat Cancer. 2015 Aug;22(4):665-78. doi: 10.1530/ERC-15-0277. Epub 2015 Jun 25. PMID: 26113609; PMCID: PMC4526795. 4. Xu D, Rowland SE, Clark P, Giroux A, Côté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N, Mancini J, Audoly L, Riendeau D. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. doi: 10.1124/jpet.108.138776. Epub 2008 Jun 4. PMID: 18524979.
In vitro protocol:
1. Tuure L, Pemmari A, Hämäläinen M, Moilanen T, Moilanen E. Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. Br J Pharmacol. 2020 Sep;177(18):4134-4146. doi: 10.1111/bph.15142. Epub 2020 Aug 10. PMID: 32449517; PMCID: PMC7443472. 2. Hétu PO, Ouellet M, Falgueyret JP, Ramachandran C, Robichaud J, Zamboni R, Riendeau D. Photo-crosslinking of proteins in intact cells reveals a dimeric structure of cyclooxygenase-2 and an inhibitor-sensitive oligomeric structure of microsomal prostaglandin E2 synthase-1. Arch Biochem Biophys. 2008 Sep 1;477(1):155-62. doi: 10.1016/j.abb.2008.04.038. Epub 2008 May 6. PMID: 18498757.
In vivo protocol:
1. Finetti F, Terzuoli E, Giachetti A, Santi R, Villari D, Hanaka H, Radmark O, Ziche M, Donnini S. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity. Endocr Relat Cancer. 2015 Aug;22(4):665-78. doi: 10.1530/ERC-15-0277. Epub 2015 Jun 25. PMID: 26113609; PMCID: PMC4526795. 2. Xu D, Rowland SE, Clark P, Giroux A, Côté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N, Mancini J, Audoly L, Riendeau D. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. doi: 10.1124/jpet.108.138776. Epub 2008 Jun 4. PMID: 18524979.
1: Xu D, Rowland SE, Clark P, Giroux A, Côté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N, Mancini J, Audoly L, Riendeau D. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. doi: 10.1124/jpet.108.138776. Epub 2008 Jun 4. PubMed PMID: 18524979.